These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16635086)

  • 1. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
    Liam CK; Pang YK; Leow CH
    Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
    Kim JE; Lee DH; Choi Y; Yoon DH; Kim SW; Suh C; Lee JS
    Lung Cancer; 2009 Sep; 65(3):351-4. PubMed ID: 19157632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
    Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
    Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma.
    Wang H; Zhang G; Li P; Yan X; Wang Q; Zhu H; Qi G; Fan Q; Ma Z
    Pharmazie; 2012 Jan; 67(1):80-5. PubMed ID: 22393836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
    Lee DH; Han JY; Lee HG; Lee JJ; Lee EK; Kim HY; Kim HK; Hong EK; Lee JS
    Clin Cancer Res; 2005 Apr; 11(8):3032-7. PubMed ID: 15837758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
    Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
    Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
    Acharyya S; Sau S; Dasgupta P; Chakraborty A; Gangopadhyay S
    J Indian Med Assoc; 2012 Jul; 110(7):474-6, 493. PubMed ID: 23520673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
    Argiris A; Mittal N
    Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
    Reck M; Gatzemeier U
    Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
    Kobayashi M; Matsui K; Katakami N; Takeda K; Moriyama A; Iwamoto Y; Takada M; Yoshioka H; Sueoka-Aragane N; Nakagawa K;
    Jpn J Clin Oncol; 2011 Aug; 41(8):948-52. PubMed ID: 21715363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
    Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
    J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
    van Puijenbroek R; Bosquée L; Meert AP; Schallier D; Goeminne JC; Tits G; Collard P; Nackaerts K; Canon JL; Duplaquet F; Galdermans D; Germonpré P; Azerad MA; Vandenhoven G; De Greve J; Vansteenkiste J
    Eur Respir J; 2007 Jan; 29(1):128-33. PubMed ID: 17005582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
    Koizumi T; Agatsuma T; Ikegami K; Suzuki T; Kobayashi T; Kanda S; Yoshikawa S; Kubo K; Shiina T; Takasuna K; Matsuo A; Hayasaka M; Morikawa M; Ameshima S
    Clin Lung Cancer; 2012 Nov; 13(6):458-63. PubMed ID: 22402083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
    Oh IJ; Ban HJ; Kim KS; Kim YC
    Lung Cancer; 2012 Jul; 77(1):121-7. PubMed ID: 22333554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
    Lie CH; Chang HC; Chao TY; Chung YH; Wang JL; Wang CC; Lin MC
    Clin Lung Cancer; 2011 Mar; 12(2):116-24. PubMed ID: 21550558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.